Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Genor Biopharma Holdings Limited ( (HK:6998) ) is now available.
Genor Biopharma Holdings Limited has announced the extension of Dr. Guo Feng’s term as CEO for an additional two years, effective from April 16, 2025, to April 15, 2027. This decision reflects the company’s confidence in Dr. Guo’s leadership and his extensive experience in the biopharmaceutical industry, which is expected to benefit the company’s strategic direction and operational management.
More about Genor Biopharma Holdings Limited
Genor Biopharma Holdings Limited is a company in the biopharmaceutical industry, focusing on the development and commercialization of innovative biologics. The company operates primarily in the research and development sector, aiming to advance treatments in various therapeutic areas.
YTD Price Performance: 15.79%
Average Trading Volume: 1,966
Technical Sentiment Signal: Sell
Current Market Cap: €124.5M
See more insights into 6998 stock on TipRanks’ Stock Analysis page.